ARTV — Artiva Biotherapeutics, Inc. Common Stock

Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a biotechnology company listed on NASDAQ. It is led by Fred Aslan M.D., based in 5505 Morehouse Drive, San Diego, CA, United States, 92121, with about 96 employees. Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Net income was -$21.5M. ARTV currently screens at market cap $37.3M.

Use this ARTV page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ARTV quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ARTV SEC filings page. Lician reads the product cache first so this HTML stays unique to Artiva Biotherapeutics, Inc. Common Stock even when a live quote feed is slow.